Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | IDE | P14735 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29946177 | 0.91 | TDP1 (0.53) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29802482 | 0.91 | TDP1 (0.53) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL2033976 | 0.82 | PSEN1 (0.43) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5406043 | 0.81 | TDP1 (0.56) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29802348 | 0.80 | CNR1 (0.49) | TDP1CAPN1CA12CA1CA2 | |
| SCHEMBL29577715 | 0.79 | CASP3 (0.52) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31331945 | 0.79 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL17107771 | 0.79 | TDP1 (0.43) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31378083 | 0.79 | TDP1 (0.63) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31378143 | 0.78 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220017944-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2022-01-20 | — | — | US | disclosed |
| US-11021733-B2 | Stabilization and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3447141-B1 | STABILISATION OF BIOLOGICAL SAMPLES | PREANALYTIX GMBH (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-10724074-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2020-07-28 | — | — | US | disclosed |
| US-10676780-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2020-06-09 | — | — | US | disclosed |
| US-20200120923-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2020-04-23 | — | — | US | disclosed |
| EP-2976425-B1 | STABILIZATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2019-11-06 | — | — | EP | disclosed |
| US-20150275268-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2015-10-01 | — | — | US | disclosed |
| WO-2014146780-A1 | STABILIZATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146781-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014146782-A1 | STABILIZATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140227688-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140227687-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| EP-2761020-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | Qiagen GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2761000-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013045457-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013045458-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200120923-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TDP1 342/4885MEN1 1662/4885ABL1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.